查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1370916

基因治疗市场 - 2018-2028 年全球产业规模、份额、趋势、机会和预测，按载体类型、交付方法、适应症、地区、竞争细分

Gene Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Vector Type, By Delivery Method, By Indication, By Region, By Competition
出版日期: | 出版商: TechSci Research | 英文 190 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2022年全球基因治疗市场价值为60.1亿美元，预计在预测期内将大幅增长，预计复合年增长率（CAGR）为9.26%，预计到2028年将达到101.3亿美元。涉及透过修改、替换或补充导致疾病的缺失或有缺陷的基因组合来治疗疾病。它已成为对抗退化性疾病的一个非常理想的研究前沿。

主要市场驱动因素

市场概况
预测期 2024-2028
2022 年市场规模 60.1亿美元
2028 年市场规模 101.3亿美元
2023-2028 年复合年增长率 9.26%
成长最快的细分市场 非病毒载体
最大的市场 北美洲
  • 1.基因研究的进步：对疾病遗传基础的深入了解使科学家能够找出导致各种疾病的特定基因。这些知识对于开发精确的基因疗法至关重要，这些疗法可以纠正或替换有缺陷的基因，解决疾病的根本原因。 CRISPR-Cas9、TALEN 和锌指核酸酶等基因编辑技术的进步，透过实现准确、高效的基因修饰，彻底改变了基因疗法。这反过来又为治疗遗传性疾病开闢了新途径。
  • 2.遗传性疾病盛行率上升：被诊断为遗传性疾病的人数不断增加，凸显了对有效治疗的医疗需求尚未得到满足。基因疗法为这些疾病提供了有针对性的、持久的解决方案，这些疾病通常是症状治疗，而不是从遗传源头进行治疗。遗传性疾病的日益流行扩大了潜在的患者基础，推动了对基因治疗的需求和市场机会。
  • 3.合作与伙伴关係：基因治疗需要多学科方法，涉及分子生物学、遗传学、生物技术、临床研究和监管事务。合作有助于汇集不同领域的知识、专业知识和最佳实践，促进创新并加速更先进基因疗法的开发。合作伙伴关係提供专业技术和工具，促进基因疗法开发的突破。它们还有助于开发可扩展的製造技术，并为应对复杂的监管环境提供支持，最终促进市场成长。

主要市场挑战

  • 1.技术复杂性：有效基因疗法的开发需要对遗传学、分子生物学和复杂的细胞过程有深刻的了解。设计精确靶向和修改特定基因的疗法的复杂性可能会导致研究和开发时间延长。实现精确和受控基因传递的挑战以及潜在的意外后果造成了技术困难，影响了治疗的成功。
  • 2.开发成本高：基因治疗开发涉及大量的初始研究、大量的临床试验成本、监管合规费用以及建立熟练团队的需要。尖端技术和精密的实验室设备也导致了高昂的开发成本。由于其专业性，吸引和留住该领域的专家可能成本高昂。

主要市场趋势

  • 1.扩大治疗标靶：新治疗标靶的确定扩大了基因治疗的应用范围，包括癌症、心血管疾病、神经退化性疾病和罕见疾病等复杂疾病。这种多元化吸引了更大的患者群体，透过增加商业机会来推动市场成长。它促进创新，加速研究，并带来更多样化的临床试验环境。
  • 2.不断发展的基于CRISPR的疗法：CRISPR-Cas9技术在基因编辑方面的精确性加速了基因疗法的研究。其精确靶向和修改基因的能力提高了治疗效果和安全性。基于 CRISPR 的疗法有潜力解决从单基因到复杂病症的广泛遗传性疾病，并简化监管审批流程。 CRISPR 技术的普及刺激了全球合作，导致竞争、创新和市场扩张。

细分市场洞察

载体类型见解：预计非病毒载体市场在整个预测期内将显着成长。与病毒载体相比，非病毒载体提供了更安全的特性，并且降低了免疫反应风险。它们整合到宿主基因组的风险较低，增强了长期治疗应用。非病毒载体也简化了製造过程，有可能降低生产成本并实现可扩展性。它们的安全优势可以带来更顺畅的监管途径，加快审核速度。非病毒载体技术的出现吸引了众多产业参与者，促进了竞争、创新和市场扩张。

给药方法见解：体内细分市场因其非侵入性而占据市场主导地位，使其更容易被患者接受并降低与外科手术相关的风险。体内基因治疗可以全身进行，使其适用于更广泛的患者，并且适用于影响多个器官或组织的疾病。其全身性作用可能有益于具有广泛遗传异常的疾病，并提供持久的影响。体内基因疗法的多功能性吸引了各种各样的研究人员、开发人员和公司进入基因治疗市场。

区域洞察

北美，特别是美国，将在 2022 年成为基因治疗市场的领导者。这归功于该地区强大的研究和创新生态系统，吸引了来自不同来源的大量投资进入基因治疗研究和临床试验。北美拥有完善的临床试验基础设施、许多致力于基因治疗的生物技术公司以及先进的医疗基础设施，为基因治疗的研究、临床应用和采用创造了良好的环境。

目录

第 1 章：产品概述

  • 市场定义
  • 市场范围
    • 涵盖的市场
    • 考虑学习的年份
    • 主要市场区隔

第 2 章：研究方法

  • 研究目的
  • 基线方法
  • 主要产业伙伴
  • 主要协会和二手资料来源
  • 预测方法
  • 数据三角测量与验证
  • 假设和限制

第 3 章：执行摘要

  • 市场概况
  • 主要市场细分概述
  • 主要市场参与者概述
  • 重点地区/国家概况
  • 市场驱动因素、挑战、趋势概述

第 4 章：临床试验分析

  • 正在进行的临床试验
  • 已完成的临床试验
  • 终止的临床试验
  • 按开发阶段分類的管道细目
  • 管道细分（按状态）
  • 按研究类型分類的管道细目
  • 按地区分類的管道明细
  • 临床试验热图

第 5 章：客户之声

第 6 章：全球基因治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按载体类型（病毒载体、非病毒载体）
    • 依递送方式（体内、体外）
    • 按适应症（罕见疾病、癌症、神经系统疾病、其他）
    • 按地区（北美、欧洲、亚太地区、南美、中东和非洲）
    • 按公司划分 (2022)
  • 市场地图
    • 按向量类型
    • 按交货方式
    • 按指示
    • 按地区

第 7 章：北美基因治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按载体类型（病毒载体、非病毒载体）
    • 依递送方式（体内、体外）
    • 按适应症（罕见疾病、癌症、神经系统疾病、其他）
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 加拿大
    • 墨西哥

第 8 章：欧洲基因治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按载体类型（病毒载体、非病毒载体）
    • 依递送方式（体内、体外）
    • 按适应症（罕见疾病、癌症、神经系统疾病、其他）
    • 按国家/地区
  • 欧洲：国家分析
    • 法国
    • 德国
    • 英国
    • 义大利
    • 西班牙

第 9 章：亚太地区基因治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按载体类型（病毒载体、非病毒载体）
    • 依递送方式（体内、体外）
    • 按适应症（罕见疾病、癌症、神经系统疾病、其他）
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第 10 章：南美洲基因治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按载体类型（病毒载体、非病毒载体）
    • 依递送方式（体内、体外）
    • 按适应症（罕见疾病、癌症、神经系统疾病、其他）
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 11 章：中东和非洲基因治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按载体类型（病毒载体、非病毒载体）
    • 依递送方式（体内、体外）
    • 按适应症（罕见疾病、癌症、神经系统疾病、其他）
    • 按国家/地区
  • MEA：国家分析
    • 南非基因治疗
    • 沙乌地阿拉伯基因治疗
    • 阿联酋基因治疗

第 12 章：市场动态

  • 司机
  • 挑战

第 13 章：市场趋势与发展

  • 近期发展
  • 併购
  • 产品发布

第 14 章：全球基因治疗市场：SWOT 分析

第 15 章：资金分析

第16章：波特的五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代产品的威胁

第17章：竞争格局

  • 商业概览
  • 产品供应
  • 最近的发展
  • 财务（据报导）
  • 主要人员
  • SWOT分析
    • REGENXBIO Inc.
    • Oxford Biomedica PLC.
    • Voyager Therapeutics Inc.
    • Human Stem Cells Institute
    • Dimension Therapeutics, Inc.
    • Bristol-Myers Squibb Company
    • Sanofi-Aventis
    • Applied genetic technologies corporation.
    • F. Hoffmann-la Roche ltd.
    • Bluebird bio, Inc.
    • Novartis AG
    • Uniqure NV

第 18 章：策略建议

简介目录
Product Code: 17109

The Global Gene Therapy Market, valued at USD 6.01 Billion in 2022, is poised for substantial growth in the forecast period, with a projected Compound Annual Growth Rate (CAGR) of 9.26% and is expected to reach USD 10.13 Billion by 2028. Gene therapy involves the treatment of illnesses by modifying, replacing, or supplementing missing or defective genetic combinations responsible for the disease. It has emerged as a highly desirable research frontier in combating degenerative diseases.

The increasing prevalence of cancer and other chronic diseases worldwide is driving the need for gene therapy. Anticipated advancements in gene therapies, expected to receive approvals in the coming years, are set to contribute significantly to the growth of the gene therapy market during the forecast period. Gene therapies are designed to address diseases by altering genetic information, such as deactivating malfunctioning genes or substituting a disease-causing gene with a healthy one. This approach has demonstrated effectiveness in treating a variety of disorders, including diabetes, cancer, heart disease, and AIDS.

Key Market Drivers

Market Overview
Forecast Period2024-2028
Market Size 2022USD 6.01 Billion
Market Size 2028USD 10.13 Billion
CAGR 2023-20289.26%
Fastest Growing SegmentNon-Viral Vectors
Largest MarketNorth America
  • 1. Advancements in Genetic Research: Growing insights into the genetic basis of diseases have empowered scientists to pinpoint specific genes responsible for various disorders. This knowledge is pivotal in developing precise gene therapies that can rectify or replace defective genes, tackling the root causes of diseases. Advancements in gene editing technologies, such as CRISPR-Cas9, TALENs, and zinc finger nucleases, have revolutionized gene therapy by enabling accurate and efficient gene modifications. This, in turn, has opened new avenues for treating genetic disorders.
  • 2. Rising Prevalence of Genetic Disorders: The increasing number of individuals diagnosed with genetic disorders underscores the unmet medical need for effective treatments. Gene therapy offers targeted and long-lasting solutions for these disorders, which are often managed symptomatically rather than at their genetic source. The growing prevalence of genetic disorders expands the potential patient base, driving demand for gene therapy and market opportunities.
  • 3. Collaborations and Partnerships: Gene therapy necessitates a multidisciplinary approach, involving molecular biology, genetics, biotechnology, clinical research, and regulatory affairs. Collaborations facilitate the pooling of knowledge, expertise, and best practices across diverse fields, fostering innovation and expediting the development of more advanced gene therapies. Partnerships grant access to specialized technologies and tools, promoting breakthroughs in gene therapy development. They also aid in the development of scalable manufacturing techniques and provide support in navigating complex regulatory landscapes, ultimately contributing to market growth.

Key Market Challenges

  • 1. Technical Complexity: The development of effective gene therapies requires a profound understanding of genetics, molecular biology, and intricate cellular processes. The complexity of designing therapies that accurately target and modify specific genes can lead to prolonged research and development timelines. Challenges in achieving precise and controlled gene delivery, along with potential unintended consequences, pose technical difficulties, affecting therapy success.
  • 2. High Development Costs: Gene therapy development involves significant initial research, extensive clinical trial costs, regulatory compliance expenses, and the need to build skilled teams. Cutting-edge technologies and sophisticated laboratory equipment also contribute to high development costs. Attracting and retaining experts in the field can be expensive due to its specialized nature.

Key Market Trends

  • 1. Expanding Therapeutic Targets: The identification of new therapeutic targets broadens the scope of gene therapy applications to include complex diseases like cancer, cardiovascular diseases, neurodegenerative disorders, and rare conditions. This diversification attracts a larger patient base, driving market growth by increasing commercial opportunities. It fosters innovation, accelerates research, and results in a more diverse clinical trial landscape.
  • 2. Growing CRISPR-Based Therapies: CRISPR-Cas9 technology's precision in gene editing has accelerated gene therapy research. Its ability to target and modify genes accurately enhances therapy efficacy and safety. CRISPR-based therapies have the potential to address a wide range of genetic disorders, from monogenic to complex conditions, and simplify the regulatory approval process. The accessibility of CRISPR technology has spurred global collaboration, leading to competition, innovation, and market expansion.

Segmental Insights

Vector Type Insights: The Non-Viral Vector segment is expected to witness significant market growth throughout the forecast period. Non-viral vectors offer a safer profile with reduced immune response risks compared to viral vectors. Their lower risk of integrating into the host genome enhances long-term therapeutic applications. Non-viral vectors also simplify manufacturing processes, potentially reducing production costs and enabling scalability. Their safety advantages can lead to smoother regulatory pathways, expediting approvals. The emergence of non-viral vector technologies attracts a diverse range of industry players, promoting competition, innovation, and market expansion.

Delivery Method Insights: The In-Vivo segment has dominated the market due to its non-invasive nature, making it more acceptable to patients and reducing risks associated with surgical procedures. In vivo gene therapy can be administered systemically, making it accessible to a broader range of patients and suitable for conditions affecting multiple organs or tissues. Its systemic effect can be beneficial for diseases with widespread genetic abnormalities, offering long-lasting effects. In vivo gene therapy's versatility attracts a diverse range of researchers, developers, and companies to the gene therapy market.

Regional Insights

North America, specifically the United States, has been the leader in the gene therapy market in 2022. This is attributed to the region's robust research and innovation ecosystem, attracting significant investments from various sources into gene therapy research and clinical trials. North America boasts well-established clinical trial infrastructure, a multitude of biotechnology companies dedicated to gene therapy, and advanced healthcare infrastructure, creating a favorable environment for gene therapy research, clinical application, and adoption.

Key Market Players

  • REGENXBIO Inc.
  • Oxford Biomedica PLC.
  • Voyager Therapeutics Inc.
  • Human Stem Cells Institute
  • Dimension Therapeutics, Inc.
  • Bristol-Myers Squibb Company
  • Sanofi-Aventis
  • Applied genetic technologies corporation.
  • F. Hoffmann-la roche ltd.
  • Bluebird bio, inc.
  • Novartis ag
  • Uniqure n.v

Report Scope:

In this report, the Global Gene Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below.

Gene Therapy Market, By Vector Type:

  • Viral Vector
  • Non-Viral Vector

Gene Therapy Market, By Delivery Method:

  • In-Vivo
  • Ex-Vivo

Gene Therapy Market, By Indication:

  • Rare Diseases
  • Cancer
  • Neurological Diseases
  • Others

Gene Therapy Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Turkey
  • Egypt

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Gene Therapy Market.

Available Customizations:

  • Global Gene Therapy market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Clinical Trial Analysis

  • 4.1 Ongoing Clinical Trials
  • 4.2 Completed Clinical Trials
  • 4.3 Terminated Clinical Trials
  • 4.4 Breakdown of Pipeline, By Development Phase
  • 4.5 Breakdown of Pipeline, By Status
  • 4.6 Breakdown of Pipeline, By Study Type
  • 4.7 Breakdown of Pipeline, By Region
  • 4.8 Clinical Trials Heat Map

5. Voice of Customer

6. Global Gene Therapy Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Vector Type (Viral Vector, Non-Viral Vector)
      • 5.2.1.1 By Viral Vectors (Retro Viral Vectors, Adeno-associated Viral Vectors, Others)
      • 5.2.1.2 By Non-Viral Vectors (Oligonucleotides, Others)
    • 6.2.2. By Delivery Method (In-Vivo, Ex-Vivo)
    • 6.2.3. By Indication (Rare Diseases, Cancer, Neurological Diseases, Others)
    • 6.2.4. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
    • 6.2.5. By Company (2022)
  • 6.3. Market Map
    • 5.3.1 By Vector Type
    • 5.3.2 By Delivery Method
    • 5.3.3 By Indication
    • 5.3.4 By Region

7. North America Gene Therapy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Vector Type (Viral Vector, Non-Viral Vector)
      • 7.2.1.1 By Viral Vectors (Retro Viral Vectors, Adeno-associated Viral Vectors, Others)
      • 7.2.1.2 By Non-Viral Vectors (Oligonucleotides, Others)
    • 7.2.2. By Delivery Method (In-Vivo, Ex-Vivo)
    • 7.2.3. By Indication (Rare Diseases, Cancer, Neurological Diseases, Others)
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Gene Therapy Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Vector Type
        • 7.3.1.2.2. By Delivery Method
        • 7.3.1.2.3. By Indication
    • 7.3.2. Canada Gene Therapy Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Vector Type
        • 7.3.2.2.2. By Delivery Method
        • 7.3.2.2.3. By Indication
    • 7.3.3. Mexico Gene Therapy Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Vector Type
        • 7.3.3.2.2. By Delivery Method
        • 7.3.3.2.3. By Indication

8. Europe Gene Therapy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Vector Type (Viral Vector, Non-Viral Vector)
      • 8.2.1.1 By Viral Vectors (Retro Viral Vectors, Adeno-associated Viral Vectors, Others)
      • 8.2.1.2 By Non-Viral Vectors (Oligonucleotides, Others)
    • 8.2.2. By Delivery Method (In-Vivo, Ex-Vivo)
    • 8.2.3. By Indication (Rare Diseases, Cancer, Neurological Diseases, Others)
    • 8.2.4. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Gene Therapy Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Vector Type
        • 8.3.1.2.2. By Delivery Method
        • 8.3.1.2.3. By Indication
    • 8.3.2. Germany Gene Therapy Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Vector Type
        • 8.3.2.2.2. By Delivery Method
        • 8.3.2.2.3. By Indication
    • 8.3.3. United Kingdom Gene Therapy Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Vector Type
        • 8.3.3.2.2. By Delivery Method
        • 8.3.3.2.3. By Indication
    • 8.3.4. Italy Gene Therapy Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Vector Type
        • 8.3.4.2.2. By Delivery Method
        • 8.3.4.2.3. By Indication
    • 8.3.5. Spain Gene Therapy Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Vector Type
        • 8.3.5.2.2. By Delivery Method
        • 8.3.5.2.3. By Indication

9. Asia-Pacific Gene Therapy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Vector Type (Viral Vector, Non-Viral Vector)
      • 9.2.1.1 By Viral Vectors (Retro Viral Vectors, Adeno-associated Viral Vectors, Others)
      • 9.2.1.2 By Non-Viral Vectors (Oligonucleotides, Others)
    • 9.2.2. By Delivery Method (In-Vivo, Ex-Vivo)
    • 9.2.3. By Indication (Rare Diseases, Cancer, Neurological Diseases, Others)
    • 9.2.4. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Gene Therapy Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Vector Type
        • 9.3.1.2.2. By Delivery Method
        • 9.3.1.2.3. By Indication
    • 9.3.2. India Gene Therapy Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Vector Type
        • 9.3.2.2.2. By Delivery Method
        • 9.3.2.2.3. By Indication
    • 9.3.3. Japan Gene Therapy Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Vector Type
        • 9.3.3.2.2. By Delivery Method
        • 9.3.3.2.3. By Indication
    • 9.3.4. South Korea Gene Therapy Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Vector Type
        • 9.3.4.2.2. By Delivery Method
        • 9.3.4.2.3. By Indication
    • 9.3.5. Australia Gene Therapy Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Vector Type
        • 9.3.5.2.2. By Delivery Method
        • 9.3.5.2.3. By Indication

10. South America Gene Therapy Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Vector Type (Viral Vector, Non-Viral Vector)
      • 10.2.1.1 By Viral Vectors (Retro Viral Vectors, Adeno-associated Viral Vectors, Others)
      • 10.2.1.2 By Non-Viral Vectors (Oligonucleotides, Others)
    • 10.2.2. By Delivery Method (In-Vivo, Ex-Vivo)
    • 10.2.3. By Indication (Rare Diseases, Cancer, Neurological Diseases, Others)
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Gene Therapy Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Vector Type
        • 10.3.1.2.2. By Delivery Method
        • 10.3.1.2.3. By Indication
    • 10.3.2. Argentina Gene Therapy Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Vector Type
        • 10.3.2.2.2. By Delivery Method
        • 10.3.2.2.3. By Indication
    • 10.3.3. Colombia Gene Therapy Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Vector Type
        • 10.3.3.2.2. By Delivery Method
        • 10.3.3.2.3. By Indication

11. Middle East and Africa Gene Therapy Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Vector Type (Viral Vector, Non-Viral Vector)
      • 11.2.1.1 By Viral Vectors (Retro Viral Vectors, Adeno-associated Viral Vectors, Others)
      • 11.2.1.2 By Non-Viral Vectors (Oligonucleotides, Others)
    • 11.2.2. By Delivery Method (In-Vivo, Ex-Vivo)
    • 11.2.3. By Indication (Rare Diseases, Cancer, Neurological Diseases, Others)
    • 11.2.4. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Gene Therapy Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Vector Type
        • 11.3.1.2.2. By Delivery Method
        • 11.3.1.2.3. By Indication
    • 11.3.2. Saudi Arabia Gene Therapy Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Vector Type
        • 11.3.2.2.2. By Delivery Method
        • 11.3.2.2.3. By Indication
    • 11.3.3. UAE Gene Therapy Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Vector Type
        • 11.3.3.2.2. By Delivery Method
        • 11.3.3.2.3. By Indication

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

  • 13.1. Recent Development
  • 13.2. Mergers & Acquisitions
  • 13.3. Product Launches

14. Global Gene Therapy Market: SWOT Analysis

15. Funding Analysis

16. Porter's Five Forces Analysis

  • 16.1. Competition in the Industry
  • 16.2. Potential of New Entrants
  • 16.3. Power of Suppliers
  • 16.4. Power of Customers
  • 16.5. Threat of Substitute Products

17. Competitive Landscape

  • 17.1. Business Overview
  • 17.2. Product Offerings
  • 17.3. Recent Developments
  • 17.4. Financials (As Reported)
  • 17.5. Key Personnel
  • 17.6. SWOT Analysis
    • 15.6.1 REGENXBIO Inc.
    • 15.6.2 Oxford Biomedica PLC.
    • 15.6.3 Voyager Therapeutics Inc.
    • 15.6.4 Human Stem Cells Institute
    • 15.6.5 Dimension Therapeutics, Inc.
    • 15.6.6 Bristol-Myers Squibb Company
    • 15.6.7 Sanofi-Aventis
    • 15.6.8 Applied genetic technologies corporation.
    • 15.6.9 F. Hoffmann-la Roche ltd.
    • 15.6.10 Bluebird bio, Inc.
    • 15.6.11 Novartis AG
    • 15.6.12 Uniqure N.V.

18. Strategic Recommendations